SRPK2 and prostate cancer: Moreover, SRPK2 and PSMB2 over-expression was observed in prostate cancer, and correlated with a high Gleason score, advanced pathological stage, tumor metastasis [81], and significantly poor 10-year metastatic rate in prostate cancer, in younger men [82].